Abstract nr
Immunotherapy in Cancer
Proffered Paper Session: Immunotherapy in Cancer I
Chair: I. Melero (Spain)
09:15
14LBA
LATE BREAKING ABSTRACT:Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)
Speaker: J. Vansteenkiste (Belgium)
09:25
15LBA
LATE BREAKING ABSTRACT: High tumoral IFNγ mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients
Speaker: B. Higgs (USA)
09:35
16LBA
LATE BREAKING ABSTRACT: Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)
Speaker: B. Besse (France)
09:45
Discussant : L. Paz-Ares (Spain)
09:55
17LBA
LATE BREAKING ABSTRACT: Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC
Speaker: B. Rini (USA)
10:05
18LBA
LATE BREAKING ABSTRACT: PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer
Speaker: J. Yearley (USA)
10:15
Discussant : I. Melero (Spain)